The Pacific Cancer Care has teamed with patient recruitment specialist Deep Lens to use artificial intelligence technologies to expand its clinical trial programs.
The partnership – financial terms of which were not disclosed – will see the California-based center use Deep Lens’ proprietary Viper technology – an AI system designed to identify potential patients for clinical trials.
The plan is to screen patients in Pacific Cancer Care’s EMR (OncoEMR) and integrate molecular data feeds from Caris Life Sciences, Foundation Medicine and Guardant Health as well as all pathology feeds to automatically and match them to recruiting studies.
Zach Koontz, an oncologist at Pacific Cancer Care, cited accelerated recruitment as well as data and information management as the motivations for the agreement.
“We are excited to partner with Deep Lens to broaden our clinical research program through an increased number of trials that we can offer onsite and by expediting the time we can get patients into these trials.
“We have a very busy practice, and we look forward to leveraging other Deep Lens services to help alleviate some of the administrative tasks associated with clinical trial recruitment, so that our staff can focus more exclusively on patient care.”
Deep Lens co-founder Simon Arkell echoed this, putting the agreement in the context of a wider effort to develop cancer therapies.
“Pacific Cancer Care already has an extremely comprehensive clinical research program – they’ve been the first site to offer access to certain therapies via clinical trials and they place great importance on the role that clinical research plays in the overall acceleration of our knowledge and treatment of cancer.”
The agreement is similar to the accord Deep Lens signed with the Norton Cancer Institute, the largest provider of cancer care in the Louisville, Kentucky area in early June.
Image: Stock Photo Secrets